BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 32946352)

  • 1. Cause-Specific Mortality Following Initial Chemotherapy in a Population-Based Cohort of Patients With Classical Hodgkin Lymphoma, 2000-2016.
    Dores GM; Curtis RE; Dalal NH; Linet MS; Morton LM
    J Clin Oncol; 2020 Dec; 38(35):4149-4162. PubMed ID: 32946352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era.
    Howlader N; Mariotto AB; Besson C; Suneja G; Robien K; Younes N; Engels EA
    Cancer; 2017 Sep; 123(17):3326-3334. PubMed ID: 28464214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncancer causes of death in survivors of testicular cancer.
    Fosså SD; Gilbert E; Dores GM; Chen J; McGlynn KA; Schonfeld S; Storm H; Hall P; Holowaty E; Andersen A; Joensuu H; Andersson M; Kaijser M; Gospodarowicz M; Cohen R; Pukkala E; Travis LB
    J Natl Cancer Inst; 2007 Apr; 99(7):533-44. PubMed ID: 17405998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia.
    Hapgood G; Zheng Y; Sehn LH; Villa D; Klasa R; Gerrie AS; Shenkier T; Scott DW; Gascoyne RD; Slack GW; Parsons C; Morris J; Pickles T; Connors JM; Savage KJ
    J Clin Oncol; 2016 Jul; 34(21):2493-500. PubMed ID: 27269949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
    Hisada M; Chen BE; Jaffe ES; Travis LB
    J Natl Cancer Inst; 2007 Feb; 99(3):215-22. PubMed ID: 17284716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States.
    Phillips T; Liu N; Bloudek B; Migliaccio-Walle K; Reynolds J; Burke JM
    J Manag Care Spec Pharm; 2023 Dec; 29(12):1312-1320. PubMed ID: 37921077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
    Savage KJ; Skinnider B; Al-Mansour M; Sehn LH; Gascoyne RD; Connors JM
    Blood; 2011 Oct; 118(17):4585-90. PubMed ID: 21873543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study.
    Swerdlow AJ; Higgins CD; Smith P; Cunningham D; Hancock BW; Horwich A; Hoskin PJ; Lister A; Radford JA; Rohatiner AZ; Linch DC
    J Natl Cancer Inst; 2007 Feb; 99(3):206-14. PubMed ID: 17284715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy.
    Lagerlöf I; Holte H; Glimelius I; Björkholm M; Enblad G; Erlanson M; Fluge Ø; Fohlin H; Fosså A; Goldkuhl C; Gustavsson A; Johansson AS; Linderoth J; Nome O; Palma M; Åkesson L; Østenstad B; Raud C; Glimelius B; Molin D
    Br J Haematol; 2020 Mar; 188(5):685-691. PubMed ID: 31612478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
    Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A
    Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28,844 patients.
    Youn P; Milano MT; Constine LS; Travis LB
    Cancer; 2014 Aug; 120(15):2334-42. PubMed ID: 24752471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
    Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
    Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis.
    Gao J; Chen Y; Wu P; Wang F; Tao H; Shen Q; Wang S; Gong S; Zhang X; Zhou Z; Song X; Jia Y
    BMC Cancer; 2021 Aug; 21(1):955. PubMed ID: 34433456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
    Ramchandren R; Advani RH; Ansell SM; Bartlett NL; Chen R; Connors JM; Feldman T; Forero-Torres A; Friedberg JW; Gopal AK; Gordon LI; Kuruvilla J; Savage KJ; Younes A; Engley G; Manley TJ; Fenton K; Straus DJ
    Clin Cancer Res; 2019 Mar; 25(6):1718-1726. PubMed ID: 30617130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort.
    Hellesnes R; Myklebust TÅ; Fosså SD; Bremnes RM; Karlsdottir Á; Kvammen Ø; Tandstad T; Wilsgaard T; Negaard HFS; Haugnes HS
    J Clin Oncol; 2021 Nov; 39(32):3561-3573. PubMed ID: 34388002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: An analysis from Kentucky Cancer Registry.
    Myint ZW; Shrestha R; Siddiqui S; Slone S; Huang B; Ramlal R; Monohan GP; Hildebrandt GC; Saeed H
    Hematol Oncol Stem Cell Ther; 2020 Mar; 13(1):17-22. PubMed ID: 31629724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noncancer mortality among adolescents and young adults with cancer.
    Anderson C; Lund JL; Weaver MA; Wood WA; Olshan AF; Nichols HB
    Cancer; 2019 Jun; 125(12):2107-2114. PubMed ID: 30892701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.
    Gandikota N; Hartridge-Lambert S; Migliacci JC; Yahalom J; Portlock CS; Schöder H
    Cancer; 2015 Jun; 121(12):1985-92. PubMed ID: 25739719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Initial treatment strategy for classical Hodgkin lymphoma in adults].
    Kusumoto S
    Rinsho Ketsueki; 2021; 62(8):1102-1111. PubMed ID: 34497197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.